US5976832A
(en)
*
|
1995-03-06 |
1999-11-02 |
Tonen Corporation |
DNA encoding novel calcium-binding proteins
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
CN1147584C
(zh)
*
|
1996-05-24 |
2004-04-28 |
拜奥根有限公司 |
组织再生调节物
|
US6991790B1
(en)
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
US6171586B1
(en)
*
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
WO1999051639A1
(en)
*
|
1998-04-02 |
1999-10-14 |
Cartela Ab |
An integrin heterodimer and a subunit thereof
|
US20030055231A1
(en)
*
|
1998-10-28 |
2003-03-20 |
Jian Ni |
12 human secreted proteins
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
US7883704B2
(en)
*
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
CA2365601A1
(en)
*
|
1999-03-29 |
2000-10-05 |
Kansai Technology Licensing Organization Co., Ltd. |
Novel cytidine deaminase
|
EP2275540B1
(de)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Verfahren zur Steuerung der Aktivität von immunologisch funktionellen Molekülen
|
SE9902056D0
(sv)
*
|
1999-06-03 |
1999-06-03 |
Active Biotech Ab |
An integrin heterodimer and an alpha subunit thereof
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
US20020035107A1
(en)
*
|
2000-06-20 |
2002-03-21 |
Stefan Henke |
Highly concentrated stable meloxicam solutions
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US20020141970A1
(en)
*
|
2001-03-05 |
2002-10-03 |
Pettit Dean K. |
Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
|
US20040234524A1
(en)
*
|
2001-04-05 |
2004-11-25 |
Toshimitsu Uede |
Anti-osteopontin antibody and use thereof
|
AU2003211990A1
(en)
*
|
2002-02-14 |
2003-09-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing solution pharmaceuticals
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
EP1551869A2
(de)
|
2002-10-15 |
2005-07-13 |
Intercell AG |
Bindungdsfaktoren von gruppe b-streptococcus, dafür kodierende nukleinsäuren und verwendungen davon
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
AU2004256354B2
(en)
|
2003-07-15 |
2011-07-07 |
Chugai Seiyaku Kabushiki Kaisha |
IgM production by transformed cells and methods for quantifying said IgM production
|
EP1698640B2
(de)
|
2003-10-01 |
2019-06-19 |
Kyowa Hakko Kirin Co., Ltd. |
Verfahren zur stabilisierung von antikörpern und stabilisierte antikörperzubereitung vom lösungstyp
|
US7803914B2
(en)
|
2003-10-09 |
2010-09-28 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for stabilizing protein solutions
|
WO2005035574A1
(ja)
|
2003-10-09 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
IgM高濃度安定化溶液
|
US20070184050A1
(en)
*
|
2003-12-25 |
2007-08-09 |
Kirin Beer Kabushiki Kaisha |
Stable water-based medicinal preparation containing antibody
|
EP1568369A1
(de)
|
2004-02-23 |
2005-08-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Verwendung von Meloxicam zur Behandlung von Atemwegserkrankungen bei Schweinen
|
EP2404935A1
(de)
|
2004-03-30 |
2012-01-11 |
Glaxo Group Limited |
Immunglobuline gegen menschlisches OSM
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
AR053553A1
(es)
|
2005-03-08 |
2007-05-09 |
Pharmacia & Upjohn Co Llc |
Composicion de anticuerpos anti molecula de adhesion celular adresina mucosa (anti-madcam)
|
EP1888637A2
(de)
*
|
2005-05-19 |
2008-02-20 |
Amgen Inc. |
Zusammensetzungen und verfahren zur erhöhung der stabilität von antikörpern
|
AU2006259664A1
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
US20110008282A1
(en)
*
|
2006-05-15 |
2011-01-13 |
Xbiotech, Inc. |
IL-1alpha immunization induces autoantibodies protective against atherosclerosis
|
PT2109623E
(pt)
*
|
2006-05-22 |
2012-01-12 |
Xbiotech Inc |
Tratamento de cancro com anticorpos anti-il-1
|
MX2009003635A
(es)
*
|
2006-10-06 |
2009-04-22 |
Amgen Inc |
Formulaciones de anticuerpos estables.
|
MX2009003982A
(es)
*
|
2006-10-20 |
2009-04-27 |
Amgen Inc |
Formulaciones de polipeptido estables.
|
AU2008205512B2
(en)
|
2007-01-16 |
2014-06-12 |
Abbvie Inc. |
Methods for treating psoriasis
|
CN101679507A
(zh)
*
|
2007-03-29 |
2010-03-24 |
艾博特公司 |
结晶抗人类il-12抗体
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
WO2009117289A2
(en)
|
2008-03-18 |
2009-09-24 |
Abbott Laboratories |
Methods for treating psoriasis
|
MX2010012963A
(es)
*
|
2008-05-30 |
2011-04-05 |
Xbiotech Inc |
Anticuerpos de interleucina-1 alfa y metodos de uso.
|
CN102209557A
(zh)
*
|
2008-09-12 |
2011-10-05 |
埃克斯生物科技公司 |
靶向病原性单核细胞
|
EP2350649A4
(de)
*
|
2008-11-28 |
2012-11-14 |
Abbott Lab |
Stabile antikörperzusammensetzungen und stabilisierungsverfahren dafür
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
GB0904355D0
(en)
*
|
2009-03-13 |
2009-04-29 |
Imp Innovations Ltd |
Biological materials and uses thereof
|
EP2427211A4
(de)
*
|
2009-05-04 |
2013-05-01 |
Abbott Biotech Ltd |
Stabile formulierungen mit hoher proteinkonzentration aus menschlichen tnf-alpha-antikörpern
|
RU2012114854A
(ru)
*
|
2009-09-14 |
2013-10-27 |
Эбботт Лэборетриз |
Способы лечения псориаза
|
US20110070230A1
(en)
*
|
2009-09-24 |
2011-03-24 |
Xbiotech, Inc. |
Method and devices for identifying and treating a subject who has developed an anti-antibody response
|
WO2011049082A1
(ja)
*
|
2009-10-21 |
2011-04-28 |
国立大学法人広島大学 |
インテグリンα8β1特異的モノクローナル抗体
|
EP2528947A4
(de)
|
2010-01-28 |
2013-09-18 |
Glaxo Group Ltd |
Cd127-bindende proteine
|
WO2011098424A2
(en)
|
2010-02-09 |
2011-08-18 |
Glaxo Group Limited |
Treatment of a metabolic disorder
|
KR101903931B1
(ko)
|
2010-03-01 |
2018-10-02 |
바이엘 헬스케어 엘엘씨 |
조직 인자 경로 억제제 (tfpi)에 대한 최적화된 모노클로날 항체
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
ES2703774T3
(es)
|
2010-06-18 |
2019-03-12 |
Xbiotech Inc |
Tratamiento para la artritis
|
US10294296B2
(en)
|
2010-08-23 |
2019-05-21 |
Xbiotech, Inc. |
Treatment for neoplastic diseases
|
EP2444101A1
(de)
|
2010-10-21 |
2012-04-25 |
Universitätsklinikum Freiburg |
Selektives Targeting der CD40L/Mac-1-Interaktion mit kleinen Peptidinhibitoren und seine Verwendung zur Behandlung von Entzündungen und Atherogenese
|
MX344727B
(es)
|
2010-11-11 |
2017-01-05 |
Abbvie Biotechnology Ltd |
Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
|
US9724409B2
(en)
|
2011-04-01 |
2017-08-08 |
Xbiotech, Inc. |
Treatment of inflammatory skin disease
|
EP2702077A2
(de)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
|
CN108404127A
(zh)
|
2011-09-23 |
2018-08-17 |
埃克斯生物科技公司 |
恶病质治疗
|
US9895437B2
(en)
|
2012-04-18 |
2018-02-20 |
Valneva Austria Gmbh |
Aluminum compounds for use in therapeutics and vaccines
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
CA2883272A1
(en)
|
2012-09-02 |
2014-03-06 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9545441B2
(en)
|
2012-09-18 |
2017-01-17 |
Xbiotech, Inc. |
Treatment of diabetes
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
US10081673B2
(en)
*
|
2013-03-14 |
2018-09-25 |
Ffe Therapeutics Llc |
Compositions and methods for treating angiogenesis-related disorders
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
PL3334747T3
(pl)
|
2015-08-13 |
2024-04-02 |
Amgen Inc. |
Naładowana filtracja wgłębna białek wiążących antygen
|
WO2017049529A1
(en)
|
2015-09-24 |
2017-03-30 |
Innolife Co., Ltd. |
A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
|
AU2018220862A1
(en)
|
2017-02-16 |
2019-08-29 |
Janssen Biotech, Inc. |
Treatment of hidradenitis suppurativa
|
CN110408600A
(zh)
*
|
2018-12-10 |
2019-11-05 |
浙江工商大学 |
一株分泌抗重金属铜离子单克隆抗体的杂交瘤细胞株及其应用
|